Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06788990 is registered in ClinicalTrials.gov with Bicara Therapeutics as lead sponsor.

NCT NCT06788990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06788990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
Bicara Therapeutics
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 28, 2025
Completion date
July 31, 2029
Enrollment
650 (estimated)
Sites
231

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic head and neck squamous cell carcinoma, recurrent head and neck squamous cell carcinoma